Brooke McCormick

The final part explores individualized CAR T and bispecific therapy selection in multiple myeloma and the need for stronger academic-community collaboration.

August authors Jeff Romine, PhD, and Kofi Essel, MD, MPH, found grocery assistance linked to fewer diabetes complications and better medication adherence.

In part 2, Christos Vaklavas, MD, discusses clinical trial complexity and the shift toward more accessible treatment delivery.

Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.

Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said.

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

Authors noted that a grocery assistance benefit in commercial health plans was linked to fewer diabetes complications and improved medication adherence.

Lifetime colorectal cancer (CRC) risk was highest in highly developed countries, according to a global population-based study.

Employer health care costs are projected to rise 9.5% in 2027, surpassing $19,000 per employee amid persistent medical and drug spending pressures.

Hospice use and higher-intensity care are less common among older adults in isolated rural areas than in urban areas, highlighting rural hospice gaps.

Early findings from the CDAF-Relink program highlight gaps in re-engagement, outreach barriers, and opportunities to reconnect patients to care.

County-level CRC mortality was higher in areas with limited broadband access, higher smoking rates, and rurality.

Low fruit and vegetable intake alongside high sodium consumption remain top dietary drivers of CKD burden, with disparities by region, age, and income.

Fecal immunochemical tests (FITs) generate substantially fewer emissions than colonoscopy or CT colonography, driven largely by transportation.

Hepatitis B re-engagement efforts are underreported in lower-resource settings, highlighting gaps in care and the need for greater action.

Diet, alcohol, and physical activity offer actionable targets for clinicians managing MASLD, according to Zobair M. Younossi, MD.

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

Employers with complete claims data access deploy more cost-containment strategies as health care costs rise and employers seek greater PBM transparency.

Phase 2 data show promising antiviral activity with tobevibart plus elebsiran in hepatitis D, supporting further evaluation in the phase 3 ECLIPSE program.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

The shift toward fibrosis end points and noninvasive biomarkers in MASH trials may ease enrollment, improve assessment, and reduce biopsy use, Zobair M. Younossi, MD, said.

Extreme heat may accelerate plastic breakdown and increase microplastic exposure, with potential CV, endocrine, and skin health effects, said Eva R. Parker, MD.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

Global third-dose hepatitis B (HepB3) vaccine coverage reached 81.8% in 2023, but persistent gaps in Africa and South Asia threaten WHO elimination goals.

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

MASLD was linked to higher odds of EoE and reflux-related diseases, suggesting metabolic dysfunction may contribute to esophageal disease.

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.